Аортальний стеноз 

В.І. Павлюк , О.Й. Жарінов , Н.В. Понич

Література

1. Павлюк В.І. Практична ехокардіографія / За ред.О.Й. Жарінова.– Львів: Медицина світу, 2014.– 156 с.
2. Armstrong W.F., Ryan T., Feigenbaum H. Feigenbaum’s Echo-cardiography.– Lippincott Williams & Wilkins, 2010.– 785 p.
3. Baumgartner H., Hung J. et al. Echocardiographic assess-ment of valve stenosis: EAE/ASE recommendations forclinical practice // J. Am. Soc. Echocardiogr.– 2009.– Vol. 22.–P. 1–23.
4. Bellamy M.F., Pellikka P.A., Klarich K.W. et al. Association ofcholesterol levels, hydroxymethylglutaryl coenzyme-Areductase inhibitor treatment, and progression of aorticstenosis in the community // J. Am. Coll. Cardiol.– 2002.–Vol. 40.– P.  1723–1730.
5. Bonow R.O., Carabello B.A., Chatterjee K. et al. 2008 focusedupdate incorporated into the ACC/AHA 2006 guidelines forthe management of patients with valvular heart disease: areport of the American College of Cardiology/AmericanHeart  Association Task Force on Management of PatientsWith Valvular Heart Disease // J. Am. Coll. Cardiol.– 2008.–Vol. 52.– Р. e1–e142.
6. Brown J.M., O’Brien S.M., Wu C. et al. Isolated aortic valvereplacement in North America comprising 108,687 patientsin 10 years: changes in risks, valve types, and outcomes in theSociety of Thoracic Surgeons National Database // J.  Thorac.Cardiovasc. Surg.– 2009.– Vol. 137.– P. 82–90.
7. Chan K.L., Teo K., Dumesnil J.G. et al. Effect of Lipid loweringwith rosuvastatin on progression of aortic stenosis: results ofthe aortic stenosis progression observation: measuring effects  of rosuvastatin (ASTRONOMER) trial // Circulation.–2010.– Vol. 121.– P. 306–314.
8. Cowell S.J., Newby D.E., Prescott R.J. et al. A randomized trialof intensive lipid-lowering therapy in calcific aortic stenosis //New Engl. J. Med.– 2005.– Vol. 352.– P. 2389–2397.
9. Freeman R.V., Otto C.M. Spectrum of calcific aortic valvedisease: pathogenesis, disease progression, and treatmentstrategies // Circulation.– 2005.– Vol. 111.– P. 3316–3326.
10. Grube E., Schuler G., Buellesfeld L. et al. Percutaneous aorticvalve replacement for severe aortic stenosis in high-riskpatients using the second- and current third-generation self-expanding CoreValve prosthesis: device success and 30-    dayclinical outcome // J. Am. Coll. Cardiol.– 2007.– Vol. 50.–P. 69–76.
11. Iung B., Baron G., Butchart EG. et al. A prospective survey ofpatients with valvular heart disease in Europe: the EuroHeart Survey on valvular heart disease // Eur. Heart J.– 2003.–Vol. 24.– P. 1231–1243.
12. Lombard J.T., Selzer A. Valvular aortic stenosis. A clinical andhemodynamic profile of patients // Ann. Intern. Med.–1987.– Vol. 106.– P. 292–298.
13. Moura L.M., Ramos S.F., Zamorano J.L. et al. Rosuvastatinaffecting aortic valve endothelium to slow the progressionof aortic stenosis // J. Am. Coll. Cardiol.– 2007.– Vol. 49.P. 554–561.
14. Novaro G.M., Tiong I.Y., Pearce G.L. et al. Effect  ofhydroxymethylglutaryl coenzyme a reductase inhibitors onthe progression of calcific aortic stenosis // Circulation.–2001.– Vol. 104.– P. 2205–2209.
15. O’Brien K.D. Pathogenesis of calcific aortic valve disease: a disease process comes of age (and a good deal more) // Arterioscler. Thromb. Vasc. Biol.– 2006.– Vol. 26.– P. 1721–1728.
16. Otto C.M. Calcific aortic stenosis – time to look more closelyat the valve // New Engl. J. Med.– 2008.– Vol. 359.– P. 1395–1398.
17. Otto C.M., Lind B.K., Kitzman D.W. et al. Association ofaortic-valve sclerosis with cardiovascular mortality andmorbidity in the elderly // New Engl. J. Med.– 1999.– Vol.341.– P. 142–147.
18. Otto C.M., Mickel M.C., Kennedy J.W. et al. Three-yearoutcome after balloon aortic valvuloplasty. Insights intoprognosis of valvular aortic stenosis // Circulation.– 1994.–Vol. 89.– P. 642–650.
19. Ozumi K., Tasaki H., Yamashita K. et al. Valvular and supra-valvular aortic stenosis in heterozygous familial hyper-cholesterolemia, a case report // J. Atheroscler. Thromb.–2005.– Vol. 12.– P. 289–293
20. Piazza N., Grube E., Gerckens U. et al. Procedural and 30-dayoutcomes following transcatheter aortic valve implantationusing the third generation (18 Fr) corevalve revalving system:results from the multicentre, expanded evaluation registry1-  year following CE mark approval // EuroIntervention.–2008.– Vol. 4.– P. 242–249.
21. Ross J. Jr., Braunwald E. Aortic stenosis // Circulation.– 1968.–Vol. 38 (Suppl. 1).– P. 1–7.
22. Rosenhek R., Binder T., Porenta G. et al. Predictors of out-come in severe, asymptomatic aortic stenosis // New Engl. J.Med.– 2000.– Vol. 343.– P. 611–617.
23. Rossebo A.B., Pedersen T.R., Boman K. et al. Intensive lipidlowering with simvastatin and ezetimibe in aortic stenosis //New Engl. J. Med.– 2008.– Vol. 359.– P. 1343–1356.
24. Sharma U.C., Barenbrug P., Pokharel S. et al. Systematicreview of the outcome of aortic valve replacement in pa-tients with aortic stenosis // Ann. Thorac. Surg.– 2004.–Vol. 78.– P. 90–95.
25. Schwarz F., Baumann P., Manthey J. et al. The effect of aorticvalve replacement on survival // Circulation.– 1982.– Vol. 66.–P. 1105–1110.
26. Stewart B.F., Siscovick D., Lind B.K. et al. Clinical factorsassociated with calcific aortic valve disease. CardiovascularHealth Study // J. Am. Coll. Cardiol.– 1997.– Vol. 29.– P. 630–634.
27. Stoddard M.F., Hammons R.T., Longaker R.A. Dopplertransesophageal echocardiographic determination of aorticvalve area in adults with aortic stenosis // Amer. HeartJ.– 1996.– Vol. 132.– P. 337–342.
28. Rahimtoola S.H. Catheter balloon valvuloplasty for severecalcific aortic stenosis: a limited role // J. Am. Coll. Cardiol.–1994.– Vol. 23.– P. 1076–1078.
29. Vaquette B., Corbineau H., Laurent M. et al. Valve replace-ment in patients with critical aortic stenosis and depressedleft ventricular function: predictors of operative risk, leftventricular function recovery, and long-term outcome //Heart.–  2005.– Vol. 91.– P. 1324–1329.
30. Webb J.G., Altwegg L., Masson J.B. et al. A new transcatheteraortic valve and percutaneous valve delivery system //J. Amer. Coll. Cardiol.– 2009.– Vol. 53.– P. 1855–1858.